FDA
No application listedNo application naming CJC-1295 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDACJC-1295 no DAC: chemistry, literature and regulatory status
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is CJC-1295 no DAC?
CJC-1295 without DAC, also written modified GRF (1-29), is a 29-residue amidated analogue of growth hormone-releasing hormone with four amino acid substitutions relative to sermorelin. Most published pharmacology concerns the albumin-binding (DAC) form, not this unconjugated peptide. It is supplied here as a research material for laboratory use only.
What are the chemical facts for CJC-1295 no DAC?
- Name
- CJC-1295 no DAC
- Also written
- Mod GRF 1-29; CJC-1295 without DAC
- Sequence
- Modified GRF (1-29), Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
- Length
- 29 residues
- Molecular formula
C152H252N44O42(matches the formula computed from the sequence)- Average molecular weight
- 3367.9 g/mol
- CAS number
863288-34-0(confirmed in PubChem)- PubChem
- CID 56841945
Chemistry checked against PubChem on 2026-10-05. Where the formula can be computed from the listed sequence, it was, and the two routes agree.
How does the literature describe the mechanism of CJC-1295 no DAC?
- Growth hormone-releasing hormone acts at a pituitary G-protein-coupled receptor that was cloned in 1992; reviews describe its signal transduction and physiology.[6],[5]
- Albumin bioconjugates of GRF(1-29) were made and tested for stability against peptidase degradation and for activity at the GRF receptor.[4]
Receptor and pathway background: Growth hormone-releasing hormone receptor.
What has published research on CJC-1295 no DAC looked at?
6 studies are cited for CJC-1295 no DAC. Each is labelled by design below, and each entry says what the paper measured.
- 2 human study
- 1 analytical chemistry
- 1 chemistry
- 1 review
- 1 receptor biology
PubMed returns 34 records for the search terms published on the method page (10 of them with a review publication type, 2 with a clinical-trial publication type), checked 5 October 2026. ClinicalTrials.gov lists 1 registered studies whose intervention matches the name (1 interventional), checked 5 October 2026.
- Two clinical papers on CJC-1295 describe the albumin-binding form, whose half-life is reported as 8 days; they do not study the unconjugated peptide listed here.[3],[2]
- A review of methods to detect synthetic GHRH analogues notes that these peptides are prohibited by the World Anti-Doping Agency.[1]
Studies are listed by what they measured. Papers whose titles state an amount or schedule, or describe a clinical outcome of an approved medicine, are not listed. This is a wording rule, not a quality filter; see the method page.
What is the regulatory status of CJC-1295 no DAC?
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names CJC-1295 as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "CJC-1295". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S2.2.4The WADA 2026 Prohibited List, in force 1 January 2026 names CJC-1295 under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05.
Which studies are cited for CJC-1295 no DAC?
[1] Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13:1871-1887.
Review and validation of methods to detect synthetic GHRH analogues in anti-doping samples; notes their WADA prohibition.
[2] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91:4792-7.
Examined the pulsatile pattern of growth hormone secretion in healthy adults during continuous CJC-1295 exposure (the albumin-binding form).
[3] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91:799-805.
Randomised, placebo-controlled trials in healthy adults reporting pharmacokinetics, GH and IGF-I pharmacodynamics and safety of CJC-1295 (the albumin-binding form).
[4] Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al.. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146:3052-8.
Albumin bioconjugates of GRF(1-29): stability against peptidase degradation and activity at the GRF receptor in vitro and in vivo.
[5] Mayo KE, Miller TL, DeAlmeida V, Zheng J, Godfrey PA. The growth-hormone-releasing hormone receptor: signal transduction, gene expression, and physiological function in growth regulation. Ann N Y Acad Sci. 1996;805:184-203.
Review of GHRH receptor signal transduction, gene expression and physiological function.
[6] Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6:1734-44.
Cloning and expression of the pituitary GHRH receptor, with ligand binding and cAMP production in transfected cells.
Data dates: citations read from PubMed 2026-10-05.
Where else in the research library is CJC-1295 no DAC covered?
Who wrote this page and how is it checked?
Peptency editorial team, last reviewed 5 October 2026. Citations are read back from PubMed, chemistry is checked against PubChem, and regulator records are read from each regulator's own database on the dates shown. The method page lists every source, search term and rule. Corrections are welcome through the contact details on the About page.